Role of increased DNA replication in the carcinogenic risk of nonmutagenic chemical carcinogens

Mutation Research - Reviews in Genetic Toxicology

Volumn 365, Issue 1-3, 1996, Pages 59-69

  Cunningham, Michael L ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

hepatocarcinogenesis; hepatocellular proliferation; nonmutagenic carcinogen; peroxisome proliferation; pleiotropic effect; rodent specific carcinogenesis

Indexed keywords

CARCINOGEN; GASOLINE; LIMONENE; METHAPYRILENE; OXAZEPAM; PEROXISOME PROLIFERATOR; PHENOBARBITAL; SACCHARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER RISK; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DNA REPLICATION; FEMALE; LIVER CARCINOGENESIS; MALE; MOUSE; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; RAT; REVIEW;

ANIMALIA; RODENTIA;

EID: 0030250237     PISSN: 01651110     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1110(96)90012-3     Document Type: Article

References (59)

1. Andrews A.W., Fornwald J.A., Lijinsky W. Nitrosation and mutagenicity of some amine drugs. Toxicol. Appl. Pharmacol. 52:1980;237-244.
2. Ashby J. Consideration of CASE predictions of genotoxic carcinogenesis for omeprazole, methapyrilene and azathioprine. Mutation Res. 272:1992;1-7.
3. Ashby J., Brady A., Elcombe C.R., Elliott B.M., Ishmael J., Odum J., Tugwood J.D., Kettle S., Purchase I.F.H. Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis. Hum. Exp. Toxicol. 13:1994;S1-S117.
4. Auerbach O., Garfinkel L. Histological changes in the urinary bladder in relation to cigarette smoking and use of artificial sweeteners. Cancer. 64:1989;983-987.
5. Bayly A.C., Roberts R.A., Dive C. Suppression of liver cell apoptosis in vitro by the nongenotoxic hepatocarcinogen and peroxisome proliferator, nafenopin. J. Cell Biol. 125:1994;197-203.
6. Bentley P., Calder I., Elcombe C., Grasso P., Stringer D., Weigand H.-J. Hepatic peroxisome proliferation in rodents and its significance for humans. Food Chem. Toxicol. 31:1993;857-907.
7. 2u-globulin nephropathy. Annu. Rev. Pharmacol. Toxicol. 30:1990;349-367.
8. Borghoff S.J., Lagarde W.H. Assessment of binding of 2,4,4-trimethyl-2-pentanol to low-molecular weight proteins isolated from kidneys of male rats and humans. Toxicol. Appl. Pharmacol. 119:1993;228-235.
9. Bucher J.R., Shackleford C.C., Haseman J.K., Johnson J.D., Kurtz P.J., Persing R.L. Carcinogenicity studies of oxazepam in mice. Fund. Appl. Toxicol. 23:1994;280-297.
10. Butterworth B.E. Chemically induced cell proliferation as a predictive assay for potential carcinogenicity. Butterworth B.E., Slaga T.J. Chemically Induced Cell Proliferation: Implications for Risk Assessment. 1991;457-467 Wiley-Liss, New York.
11. Butterworth B.E., Popp J.A., Conolly R.B., Goldsworthy T.L. Chemically induced cell proliferation in carcinogenesis. Vainio H., Magee P.N., McGregor D.B., McMichael A.J. Mechanisms of Carcinogenesis in Risk Identification. 1992;279-305 IARC, Lyon, France.
12. Casciano D.A., Shaddock J.G., Talasca G. The potent hepatocarcinogen methapyrilene does not form DNA adducts in livers of Fischer 344 rats. Mutation Res. 208:1988;129-135.
13. Cohen S.M., Ellwein L.B. Cell proliferation and carcinogenesis. Science. 249:1990;1007-1011.
14. Cohen S.M., Ellwein L.B. Genetic errors, cell proliferation, and carcinogenesis. Cancer Res. 51:1991;6493-6505.
15. Cohen S.M., Lawson T.A. Rodent Bladder tumors do not always predict for humans. Cancer Lett. 93:1995;9-16.
16. Cunningham M.L., Foley J., Maronpot R.R., Matthews H.B. Correlation of hepatocarcinogenicity and hepatocellular proliferation induced by two mutagenic diaminotoluenes. Toxicol. Appl. Pharmacol. 107:1991;562-567.
17. Cunningham M.L., Matthews H.B. Relationship of hepatocarcinogenicity and hepatocellular proliferation induced by mutagenic noncarcinogens vs. carcinogens II. 1- vs. 2-nitropropane. Toxicol. Appl. Pharmacol. 110:1991;505-513.
18. Cunningham M.L., Elwell M.R., Matthews H.B. Relationship of carcinogenicity and cellular proliferation induced by mutagenic noncarcinogens vs. carcinogens III. Organophosphate pesticides vs. tris(2,3-dibromopropyl) phosphate. Fund. Appl. Toxicol. 23:1994a;363-369.
19. Cunningham M.L., Maronpot R.R., Thompson M., Bucher J.R. Early responses of the liver of B6C3F1 mice to the hepatocarcinogen oxazepam. Toxicol. Appl. Pharmacol. 124:1994b;31-38.
20. Cunningham M.L., Pippin L.L., Anderson N.L., Wenk M.L. The hepatocarcinogen methapyrilene but not the analog pyrilamine induces sustained hepatocellular replication and protein alterations in F344 rats in a 13-week feed study. Toxicol. Appl. Pharmacol. 131:1995;216-223.
21. Devereux T.R., White C.M., Sills R.C., Bucher J.R., Maronpot R.R., Anderson M.W. Low frequency of H-ras mutations in hepatocellular adenomas and carcinomas and in hepatoblastomas from B6C3F1 mice exposed to oxazepam in the diet. Carcinogenesis. 15:1994;1083-1087.
22. Diwan B.A., Rice J.M., Ward J.M. Tumor-promoting activity of benzodiazepine tranquilizers, diazepam and oxazepam in mouse liver. Carcinogenesis. 7:1986;789-794.
23. 4-ethenocytosine by lipid peroxidation products and nucleic acid bases. Chem. Res. Toxicol. 8:1995;278-283.
24. Ellwein L.B., Cohen S.M. The health risks of saccharin revisited. CRC Crit. Rev. Toxicol. 20:1990;311-326.
25. Goldsworthy T.L., Fransson-Steen R. Apoptosis and cancer risk assessment. Mutation Res. 1996;. this issue.
26. Griffin R.J., Burka L.T. The metabolism and elimination of oxazepam in mice. Drug Metab. Disposit. 21:1993;918-926.
27. Griffin R.J., Burka L.T., Cunningham M.L. Induction of hepatic drug metabolizing enzymes by prechronic oxazepam-dosed feed treatment in B6C3F1 mice. Toxicol. Lett. 76:1995;251-256.
28. Harvey S.C. Gilman A.G., Goodman L.S., Rall T.W., Murid F. Hypnotics and Sedatives. 1985;339-371 The Pharmacological Basis of Therapeutics, MacMillan, New York.
29. Hayward J.J., Shane B.S., Tindall K.R., Cunningham M.L. Differential in vivo mutagenicity of the carcinogen/non-carcinogen pair 2,4- and 2,6-diaminotoluene. Carcinogenesis. 16:1995;2429-2433.
30. He J.-S., Fulco A.J. A barbiturate-regulated protein binding to a common sequence in the cytochrome P450 genes of rodents and bacteria. J. Biol. Chem. 266:1991;7864-7869.
31. Ioannides C., Parke D.V. Induction of cytochrome P4501 as an indicator of potential chemical carcinogenesis. Drug Metab, Rev. 25:1993;485-501.
32. Jones C.R., Lubet R.A. Induction of a pleiotropic response by phenobarbital and related compounds. Biochem. Pharmacol. 44:1992;1651-1660.
33. Kasai H., Okada Y., Nishimura S., Rao M., Reddy J. Formation of 8-hydroxydeoxyguanosine in liver DNA of rats following long-term exposure to a peroxisome proliferator. Cancer Res. 49:1989;2603-2605.
34. Klaunig J.E., Siglin J.C., Schafter L.D., Harnett J.A., Weghorst C.M., Olson M.J., Hampton J.A. Correlation between Species and Tissue Sensitivity to Chemical Carcinogenesis in Rodents and the Induction of DNA Synthesis. Butterworth B.E., Slaga T.J. Chemically Induced Cell Proliferation: Implications for Risk Assessment. 1991;185-194 Wiley-Liss, New York.
35. Lake B.G. Mechanisms of hepatocarcinogenicity of peroxisome-proliferating drugs and chemicals. Cho A.K., Blaschke T.F., Loh H.H., Way J.L. Annual Review of Pharmacology and Toxicology. vol 35:1995;483-507 Annual Reviews, Palo Alto, CA.
36. Lijinsky W. Chronic toxicity tests of pyrilamine maleate and methapyrilene hydrochloride in F344 rats. Food Chem. Toxicol. 22:1984;27-30.
37. 32P-postlabeling. Cancer Res. 48:1988;6475-6477.
38. Lijinsky W., Reuber M.D., Blackwell B.N. Liver tumors induced in rats by oral administration of the antihistaminic methapyrilene hydrochloride. Science. 209:1980;817-820.
39. Marsman D.S., Cattley R.C., Conway J.G., Popp J.A. Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643) in rats. Cancer Res. 48:1988;6739-6744.
40. Marsman D.S., Goldsworthy T.L., Popp J.A. Contrasting hepatocyte peroxisome proliferation, lipofuscin accumulation and cell turnover for the hepatocarcinogens WY-14,643 and a clofibric acid. Carcinogenesis. 13:1992;1011-1017.
41. McClain R.M. The significance of hepatic microsomal enzyme induction and altered thyroid function in rats: Implications for thyroid gland neoplasia. Toxicol. Pathol. 17:1989;294-306.
42. McClain R.M., Levin A.A., Posch R., Downing J.C. The effect of phenobarbital on the metabolism and excretion of thyroxine in rats. Toxicol. Appl. Pharmacol. 99:1989;216-228.
43. McQueen C.A., Williams G.M. Characterization of DNA repair elicited by carcinogens and drugs in the hepatocyte primary culture/DNA repair tests. J. Toxicol. Environ. Health. 8:1981;463-467.
44. Mirsalis J.C. Genotoxicity, toxicity, and carcinogenicity of the antihistamine methapyrilene. Mutation Res. 185:1987;309-317.
45. U.S.Department of Health and Human Services, Public Health Service, National Institutes of Health. National Toxicology Program Technical Report Series No 443. Toxicology and Carcinogenesis Studies of Oxazepam (CAS No. 604-75-1) in Swiss-Webster and B6C3F1 Mice. NIH Publication No. 1993;92-3359.
46. Parke D.V. The cytochromes P450 and mechanisms of chemical carcinogenesis. Environ. Health Perspect. 102:1994;852-853.
47. Popp J.A., Marsman D.S. Chemically induced cell proliferation in liver carcinogenesis, Butterworth B.E., Slaga T.J. Chemically Induced Cell Proliferation: Implications for Risk Assessment. 1991;389-395 Wiley-Liss, New York.
48. Preston-Martin S., Pike M.C., Ross R.K., Jones P.A., Henderson B.E. Increased cell division as a cause of human cancer. Cancer Res. 50:1990;7415-7421.
49. Putman D.L., San R.H.C., Bigger A.H., Jacobson-Kram D. Genetic toxicology. Derelanko M.J., Hollinger M.A. CRC Handbook of Toxicology. 1995;337-355 CRC Press, New York.
50. Ray J.S., Harbison M.L., McClain R.M., Goodman J.I. Alterations in the methylation status and expression of the raf oncogene in phenobarbital-induced and spontaneous B6C3F1 mouse liver tumors. Mol. Carcinogen. 9:1994;155-166.
51. Reddy J.K., Lalwani N.D. Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. CRC Crit. Rev. Toxicol. 12:1983;1-58.
52. Rosenkranz H.S., Klopman G. Methapyrilene: DNA as a possible target. Mutation Res. 245:1990;239-243.
53. Sharma R.K., Lake B.G., Foster J., Gibson G.G. Microsomal cytochrome P452 induction and peroxisome proliferation by hypolipidaemic agents in the rat liver. Biochem. Pharmacol. 37:1988;1193-1201.
54. Steinmetz K.L., Tyson C.K., Meierhenry E.F., Spalding J.W., Mirsalis J.C. Examination of genotoxicity, toxicity and morphological alterations in hepatocytes following in vivo or in vitro exposure to methapyrilene. Carcinogenesis. 9:1988;959-963.
55. Swenberg J.A., Dietrich D.R., McClain R.M., Cohen S.M. Species-specific mechanisms of carcinogenesis. Vainio H., Magee P.N., McGregor D.B., McMichael A.J. Mechanisms of Carcinogenesis in Risk Identification. 1992;477-500 International Agency for Research in Cancer, Lyon, France.
56. Trosko J.E., Horrobin D.P. The activity of diazepam in a Chinese hamster V79 lung cell assay for tumour promoters. IRCS J. Med Sci. 8:1980;887-893.
57. Tugwood J.D., Issemann I., Anderson R.G., Bundell K.R., McPheat W.L., Green S. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 11:1992;433-439.
58. ± mouse lymphoma assay. Mutation Res. 189:1987;285-297.
59. Upadhya P., Rao M.V., Venkateswar V., Rangarajan P.N., Padmanaban G. Identification and functional characterization of a cis-acting positive DNA element regulating CYP2B1/2B2 gene transcription in rat liver. Nucleic Acids Res. 20:1992;557-562.